# Vaccination Against Herpes Zoster in Patients With Inflammatory Rheumatic Diseases

> **NCT06763783** · PHASE4 · ENROLLING_BY_INVITATION · sponsor: **Region Skane** · enrollment: 240 (estimated)

## Conditions studied

- Systemic Vasculitis
- Spondylarthropathies
- Psoriatic Arthritis
- Scleroderma
- Polymyalgia Rheumatica (PMR)
- Juvenile Chronic Arthritis
- Polyarthritis
- SLE
- Giant Cell Arteritis (GCA)

## Interventions

- **DRUG:** Shingrix
- **DRUG:** vaccination with 2 doses of Shingrix vaccine

## Key facts

- **NCT ID:** NCT06763783
- **Lead sponsor:** Region Skane
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2024-12-17
- **Primary completion:** 2029-12-31
- **Final completion:** 2034-06-30
- **Target enrollment:** 240 (ESTIMATED)
- **Last updated:** 2025-01-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06763783

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06763783, "Vaccination Against Herpes Zoster in Patients With Inflammatory Rheumatic Diseases". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06763783. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*